Mark Wrona

MS ^E with mass defect filtering for <i>in vitro</i> and <i>in vivo</i> metabolite identification

Kevin P. Bateman, José Castro‐Perez, Mark Wrona et al. · Rapid Communications in Mass Spectrometry · 2007 · 254 citations

Life Sciences, Pharmacokinetics, Pharmacology +14

‘All‐in‐One’ analysis for metabolite identification using liquid chromatography/hybrid quadrupole time‐of‐flight mass spectrometry with collision energy switching

Mark Wrona, Timo Mauriala, Kevin P. Bateman et al. · Rapid Communications in Mass Spectrometry · 2005 · 174 citations

Life Sciences, Pharmaceutical Analysis, Pharmacology +17

Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain

John Colucci, Michael J. Boyd, Carl Berthelette et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 39 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

The Discovery of 4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic Acid (MK-2894), A Potent and Selective Prostaglandin E₂Subtype 4 Receptor Antagonist

Marc Blouin, Yongxin Han, Jason D. Burch et al. · Journal of Medicinal Chemistry · 2010 · 34 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Solution NMR Structure and X-ray Absorption Analysis of the C-Terminal Zinc-Binding Domain of the SecA ATPase

Brian R. Dempsey, Mark Wrona, Jana M. Moulin et al. · Biochemistry · 2004 · 32 citations

Life Sciences, Biochemistry, Molecular Biology +17